IUGR and infections

Area of Science:

• Perinatology
• Immunology
• Neonatology

Background:

• Intra-uterine growth retardation (IUGR) signifies impaired fetal growth, with infants classified as small for gestational age (SGA) if birth weight is below the 10th percentile.
• Congenital infections (e.g., CMV, rubella) are linked to 5-15% of IUGR cases.
• SGA preterm infants exhibit increased susceptibility to post-natal and nosocomial infections compared to SGA infants.

Purpose of the Study:

• To investigate the increased risk of post-natal infections in SGA preterm infants.
• To explore the role of immune system development in IUGR-associated infections.
• To evaluate the efficacy of current immune therapies in preventing sepsis in SGA infants.

Main Methods:

• Review of existing literature on IUGR, SGA, congenital infections, and immune system development.
• Analysis of studies examining immune parameters in SGA infants, including thymus size and leukocyte counts.
• Assessment of clinical trial data for immune therapies like intravenous immunoglobulins and GM-CSF.

Main Results:

• SGA preterm infants demonstrate a higher incidence of post-natal infections.
• Retarded immune system development, including a small thymus and reduced leukocyte counts, is observed in SGA infants.
• Prophylactic immune therapies have not effectively reduced sepsis incidence in this population.

Conclusions:

• SGA preterm infants are at significant risk for post-natal infections due to immune system deficits.
• Further research is crucial to develop effective strategies for preventing and treating infections in SGA infants.
• The current understanding suggests a need for novel immune-modulating approaches for IUGR and SGA populations.